Payment overview · 2025
General Payments
$601.13
29 reported records · 7 companies
Healthcare provider profile · identity verified
Mark P Batrice, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARLINGTON, TX · NPI 1164478038
Verified facts
What the public records show
CMS Open Payments records show Mark P Batrice, M.D. received $601.13 in general payments during 2025 across 29 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $158.94 | 26.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.04 | 24.3% | 15 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $128.25 | 21.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.52 | 16.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.27 | 5.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.98 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.13 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $601.13 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $158.94 | 4 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $128.25 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $124.36 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.62 | 4 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $78.62 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.00 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.68 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.09 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 294 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 195 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 115 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
93 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
294 | 60 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
195 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
115 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
294 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 708 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 102 |
| Furosemide | Furosemide | 475 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 121 |
| Gabapentin | Gabapentin | 355 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 99 |
| Lisinopril | Lisinopril | 332 | 93 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 331 | 59 |
| Azithromycin | Azithromycin | 327 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 97 |
| Eliquis | Apixaban | 294 | 60 |
| Alprazolam | Alprazolam | 266 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 246 | 79 |
| Potassium Chloride | Potassium Chloride | 233 | 70 |
| Metformin Hcl | Metformin Hcl | 223 | 72 |
| Carvedilol | Carvedilol | 222 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 216 | 125 |
| Tramadol Hcl | Tramadol Hcl | 216 | 50 |
| Omeprazole | Omeprazole | 212 | 65 |
| Cefuroxime | Cefuroxime Axetil | 211 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 67 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 201 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 54 |
| Temazepam | Temazepam | 198 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 197 | 53 |
| Ozempic | Semaglutide | 195 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 54 |
| Montelukast Sodium | Montelukast Sodium | 174 | 53 |
| Clonazepam | Clonazepam | 163 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 43 |
| Meloxicam | Meloxicam | 152 | 51 |
| Allopurinol | Allopurinol | 151 | 46 |
| Dexamethasone | Dexamethasone | 150 | 90 |
| Trazodone Hcl | Trazodone Hcl | 150 | 44 |
| Losartan Potassium | Losartan Potassium | 147 | 43 |
| Sertraline Hcl | Sertraline Hcl | 147 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 18 |
| Nifedipine Er | Nifedipine | 132 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 28 |
| Rybelsus | Semaglutide | 115 | 32 |
| Famotidine | Famotidine | 113 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 35 |
| Mounjaro | Tirzepatide | 107 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 37 |
| Finasteride | Finasteride | 104 | 32 |
| Donepezil Hcl | Donepezil Hcl | 101 | 21 |
| Linzess | Linaclotide | 93 | 35 |
| Glipizide | Glipizide | 91 | 26 |
| Fluconazole | Fluconazole | 88 | 33 |
| Spironolactone | Spironolactone | 86 | 28 |
| Lorazepam | Lorazepam | 82 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 33 |
| Prednisone | Prednisone | 78 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 15 |
| Mupirocin | Mupirocin | 74 | 52 |
| Ibandronate Sodium | Ibandronate Sodium | 73 | 26 |
| Memantine Hcl | Memantine Hcl | 73 | 16 |
| Alendronate Sodium | Alendronate Sodium | 72 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 22 |
| Levetiracetam | Levetiracetam | 67 | 17 |
| Metformin Hcl Er | Metformin Hcl | 66 | 25 |
| Pregabalin | Pregabalin | 65 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | 19 |
| Metronidazole | Metronidazole | 63 | 43 |
| Clonidine Hcl | Clonidine Hcl | 62 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 28 |
| Nystatin | Nystatin | 61 | 36 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 60 | 12 |
| Methocarbamol | Methocarbamol | 59 | 24 |
| Celecoxib | Celecoxib | 58 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 57 | 19 |
| Mirtazapine | Mirtazapine | 57 | 13 |
| Propranolol Hcl | Propranolol Hcl | 54 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 17 |
| Sucralfate | Sucralfate | 53 | 21 |
| Buspirone Hcl | Buspirone Hcl | 52 | 14 |
| Estradiol | Estradiol | 51 | 22 |
| Megestrol Acetate | Megestrol Acetate | 51 | 20 |
| Ondansetron Odt | Ondansetron | 47 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 14 |
| Jardiance | Empagliflozin | 45 | 12 |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Lactulose | Lactulose | 43 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Ofloxacin | Ofloxacin | 40 | 26 |
| Amoxicillin | Amoxicillin | 38 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | 15 |
| Midodrine Hcl | Midodrine Hcl | 36 | 22 |
| Telmisartan | Telmisartan | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Hydrocortisone | Hydrocortisone | 33 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 16 |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 28 | 12 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Baclofen | Baclofen | 27 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 12 |
| Torsemide | Torsemide | 27 | 11 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 16 |
| Atenolol | Atenolol | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 22 |
| Promethazine Hcl | Promethazine Hcl | 24 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Lidocaine | Lidocaine | 22 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Cephalexin | Cephalexin | 17 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | 12 |
| Silodosin | Silodosin | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $601.13 · 29 records | Bayer Healthcare Pharmaceuticals Inc. | CAMZYOS, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, Kerendia, LINZESS, Ozempic, QULIPTA, Rybelsus, UBRELVY, VIBERZI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error